Difference between revisions of "Ticlopidine (Ticlid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Jwarner moved page Ticlodipine (Ticlid) to Ticlopidine (Ticlid): typo)
m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex")
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
  
 
==Also known as==
 
==Also known as==
Line 14: Line 14:
 
[[Category:P2Y12 ADP inhibitors]]
 
[[Category:P2Y12 ADP inhibitors]]
  
[[Category:Drugs FDA approved in 2001]]
+
[[Category:FDA approved in 2001]]

Latest revision as of 01:48, 29 June 2024

General information

Class/mechanism: Irreversible thienopyridine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Also known as

  • Brand names: Ticlid, Tilopin